Jan Chrastina

Prof. Dr. Jan Chrastina


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
JCJan Chrastina
Jan Chrastina
ZNZdeněk Novák
Zdeněk Novák
TZTomáš Zeman
Tomáš Zeman
JKJitka Kočvarová
Jitka Kočvarová
MPMartin Pail
Martin Pail
MBMilan Brázdil
Milan Brázdil

1 February 2015 in Epilepsy Research
Verified
Journal Article
Closed access
MRMichal Ryzí
Michal Ryzí
MBMilan Brázdil
Milan Brázdil
ZNZdeněk Novák
Zdeněk Novák
JHJan Hemza
Jan Hemza
JCJan Chrastina
Jan Chrastina
RKRobert Kuba
Robert Kuba

27 November 2017 in Journal of Neurological Surgery Part A: Central European Neurosurgery
Verified
Journal Article
Closed access
PDF file
JKJitka Kocvarova
Jitka Kocvarova
ZNZdenek Novak
Zdenek Novak
IDIrena Dolezalova
Irena Dolezalova
MSMichal Svoboda
Michal Svoboda
MBMilan Brázdil
Milan Brázdil
JCJan Chrastina
Jan Chrastina
Introduction We analyzed the results of vagus nerve stimulation (VNS) on older patients and patients with long-lasting epilepsy and included severely intellectually disabled patients. Patients and Methods A total of 103 adults with VNS implanted from 2005 to 2014 were studied. The responder rates, that is, the percentage of VNS patients who responded to VNS, classified as seizure reduction ≥ 50% (50R) and seizure reduction ≥ 90% (90R), were compared in defined age groups (< 40 and ≥ 40 years, and < 50 and ≥ 50 years) and epilepsy duration groups (< 20 and ≥ 20 years, < 30 and ≥ 30 years, and < 40 and ≥ 40 years) at the 1-year follow-up visit and the last follow-up visit (at least 2 years after surgery). The age distributions and responder rates were also studied in patients with an intellectual disability. Results The analysis did not confirm a significantly lower 50R or 90R rate in patients ≥ 40, ≥ 50, or ≥ 60 years when compared with their younger counterparts, but the 50R rate increase during follow-up care was the lowest in patients ≥ 50 and ≥ 60 years. The highest percentage of patients with an intellectual disability in the group < 40 years of age did not adversely affect the 50R rate. Longer epilepsy duration was not confirmed as a negative predictor of VNS outcome. There was a significantly higher 50R rate in patients with epilepsy duration ≥ 20 years (at the last follow-up visit) and a higher 90R rate in patients with epilepsy duration ≥ 30 years (at the 1-year follow-up visit). The increase in the 50R rate during follow-up care was lower in patients with epilepsy durations ≥ 30 and ≥ 40 years. Conclusions The study did not find worse VNS outcomes, as defined by the 50R or 90R rate, in older adult patients or in patients with a longer epilepsy duration. The increasing stimulation effect over time is less marked in older patients and in patients with longer epilepsy duration.

1 May 2018 in World Neurosurgery
Verified
Journal Article
Closed access
JCJan Chrastina
Jan Chrastina
ZNZdeněk Novák
Zdeněk Novák
TZTomáš Zeman
Tomáš Zeman
VFVěra Feitová
Věra Feitová
DHDušan Hrabovský
Dušan Hrabovský
IŘIvo Říha
Ivo Říha

23 January 2019 in European Journal of Trauma and Emergency Surgery
Verified
Journal Article
Closed access
PDF file
JCJan Chrastina
Jan Chrastina
ČŠČeněk Šilar
Čeněk Šilar
TZTomáš Zeman
Tomáš Zeman
MSMichal Svoboda
Michal Svoboda
JKJan Krajsa
Jan Krajsa
ZNZdeněk Novák
Zdeněk Novák

4 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MHMichal Hendrych
Michal Hendrych
PSPeter Solár
Peter Solár
MHMarketa Hermanova
Marketa Hermanova
Ondrej SlabyOndrej Slaby
Ondrej Slaby
HVHana Valekova
Hana Valekova
RJRadim Jancalek
Radim Jancalek
Glioblastoma (GBM) is regarded as an aggressive brain tumor that rarely develops extracranial metastases. Despite well-investigated molecular alterations in GBM, there is a limited understanding of these associated with the metastatic potential. We herein present a case report of a 43-year-old woman with frontal GBM with primitive neuronal component who underwent gross total resection followed by chemoradiation. Five months after surgery, the patient was diagnosed with an intraspinal GBM metastasis. Next-generation sequencing analysis of both the primary and metastatic GBM tissues was performed using the Illumina TruSight Tumor 170 assay. The number of single nucleotide variants observed in the metastatic sample was more than two times higher. Mutations in TP53, PTEN, and RB1 found in the primary and metastatic tissue samples indicated the mesenchymal molecular GBM subtype. Among others, there were two inactivating mutations (Arg1026Ile, Trp1831Ter) detected in the NF1 gene, two novel NOTCH3 variants of unknown significance predicted to be damaging (Pro1505Thr, Cys1099Tyr), one novel ARID1A variant of unknown significance (Arg1046Ser), and one gene fusion of unknown significance, EIF2B5-KIF5B, in the metastatic sample. Based on the literature evidence, the alterations of NF1, NOTCH3, and ARID1A could explain, at least in part, the acquired invasiveness and metastatic potential in this particular GBM case.